Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Adverse drug reactions associated with asthma medications in children: systematic review of clinical trials.

Aagaard L, Hansen EH.

Int J Clin Pharm. 2014 Apr;36(2):243-52. doi: 10.1007/s11096-014-9924-y. Epub 2014 Feb 23. Review.

PMID:
24562976
2.

Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011.

Aagaard L, Hansen EH.

Int J Clin Pharm. 2014 Dec;36(6):1222-9. doi: 10.1007/s11096-014-0020-0. Epub 2014 Oct 7.

PMID:
25288145
5.

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.

Main C, Shepherd J, Anderson R, Rogers G, Thompson-Coon J, Liu Z, Hartwell D, Loveman E, Green C, Pitt M, Stein K, Harris P, Frampton GK, Smith M, Takeda A, Price A, Welch K, Somerville M.

Health Technol Assess. 2008 May;12(20):1-174, iii-iv. Review.

6.

Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.

Ram FS, Cates CJ, Ducharme FM.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003137. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD003137.

PMID:
15674901
7.

Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.

Lasserson TJ, Ferrara G, Casali L.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD004106. doi: 10.1002/14651858.CD004106.pub4. Review.

PMID:
22161385
8.

Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.

Cates CJ, Lasserson TJ, Jaeschke R.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006922. doi: 10.1002/14651858.CD006922.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;3:CD006922.

PMID:
19588410
9.

Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events.

Cates CJ, Lasserson TJ, Jaeschke R.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006924. doi: 10.1002/14651858.CD006924.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;6:CD006924.

PMID:
19370661
10.

Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.

Ducharme FM, Lasserson TJ, Cates CJ.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003137. Review. Update in: Cochrane Database Syst Rev. 2011;(5):CD003137.

PMID:
17054161
11.

Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.

Cates CJ, Lasserson TJ.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007695. doi: 10.1002/14651858.CD007695.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;3:CD007695.

PMID:
19821436
12.
13.

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.

Shepherd J, Rogers G, Anderson R, Main C, Thompson-Coon J, Hartwell D, Liu Z, Loveman E, Green C, Pitt M, Stein K, Harris P, Frampton GK, Smith M, Takeda A, Price A, Welch K, Somerville M.

Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. Review.

14.

Ethnic differences in adverse drug reactions to asthma medications: a systematic review.

Hu Y, Cantarero-Arévalo L.

J Asthma. 2016;53(1):69-75. doi: 10.3109/02770903.2015.1058395. Epub 2015 Sep 12. Review.

PMID:
26365429
15.

The use of inhaled formoterol in the treatment of asthma.

Berger WE.

Ann Allergy Asthma Immunol. 2006 Jul;97(1):24-33. Review. Erratum in: Ann Allergy Asthma Immunol. 2006 Oct;97(4):562. Dosage error in article text.

PMID:
16892777
16.

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.

Ni Chroinin M, Greenstone IR, Danish A, Magdolinos H, Masse V, Zhang X, Ducharme FM.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD005535. Review. Update in: Cochrane Database Syst Rev. 2010;(5):CD005535.

PMID:
16235410
17.

Safety of inhaled fluticasone propionate therapy for pediatric asthma - a systematic review.

Muley P, Shah M, Muley A.

Curr Drug Saf. 2013 Jul;8(3):186-94. Review.

PMID:
23859431
18.

Information about adverse drug reactions reported in children: a qualitative review of empirical studies.

Aagaard L, Christensen A, Hansen EH.

Br J Clin Pharmacol. 2010 Oct;70(4):481-91. doi: 10.1111/j.1365-2125.2010.03682.x. Review.

19.

Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma.

Greenstone IR, Ni Chroinin MN, Masse V, Danish A, Magdalinos H, Zhang X, Ducharme FM.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD005533. Review. Update in: Cochrane Database Syst Rev. 2010;(4):CD005533.

PMID:
16235409
20.

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.

Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL.

Pediatrics. 2001 Sep;108(3):E48.

PMID:
11533366

Supplemental Content

Support Center